EC Approves Ribociclib/Aromatase Inhibitor For HR+/HER2– Early Breast Cancer
The European Commission has approved ribociclib plus an aromatase inhibitor for patients with early breast cancer.
Managing Risks, Planning Treatment, & Making Progress in Pancreatic Cancer
A nurse practitioner discussed risk factors, diagnostic challenges, and treatment planning in patients with pancreatic cancers.
Biomarker Testing, Targeted Agents May Impact RAS+ Pancreatic Cancer Care
Shubham Pant, MD, MBBS, highlights how pan-RAS inhibitors, RAS-directed vaccines, and biomarker testing can improve outcomes in pancreatic cancer.
Advancing Research and Targeting Genomic Alterations in Pancreatic Cancer
Tanios S. Bekaii-Saab, MD, provides an overview of current therapy options and ongoing initiatives involving targetable alterations in those with pancreatic cancer.
ASTRO Guideline Recommends EBRT for Symptomatic Bone Metastases
ASTRO assembled a task force to create a guideline for the administration of palliative external beam radiation therapy for patients with symptomatic bone metastases.
Tislelizumab/Chemo Approved by European Commission For ESCC/GEJ
The European Commission has approved tislelizumab plus chemotherapy as treatment for patients with esophageal and gastric or GEJ cancer.
